Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 13 | Mind Blowing Facts

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.

Benzinga

GSK’s Emma Walmsley to step down as chief executive after eight years

Chief commercial officer Luke Miels to take over as CEO at Britain’s second-biggest drugmaker

The Guardian - UK

Pfizer sued in US over contraceptive that women say caused brain tumours

US class action lawsuit alleges company failed to warn about risks of using contraceptive injection Depo-Provera

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Trump's epic economic and drug figures fizzle under scrutiny

Trump's claims on tariff revenue and decreasing drug prices clash with expert data.

Axios

NHS facing ‘critical threat’ after Trump pressure to hike drug prices

NEWS ANALYSIS: Drug prices in the UK could rise amid 100 per cent tariffs on branded medicines and pressure from US President Donald Trump to stop ‘global freeloading’, Alicja Hagopian reports

The Independent UK

The Nations And Firms Threatened By Trump's Pharma Tariffs

Donald Trump has shocked the global drug industry by announcing 100-percent tariffs on all branded, imported pharmaceutical products -- unless companies are building manufacturing plants in the United States.

International Business Times

Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Calls for Covid vaccine boycott spur tensions in French pharmacy sector

As French pharmacists call for a boycott of Covid-19 vaccine orders, professional bodies and unions have issued stern warnings over the threat to public health.

Radio France Internationale

UK fuel retailers accused of ‘ripping off’ motorists at the pumps; markets shrug off latest Trump tariffs – as it happened

Rolling coverage of the latest economic and financial news

The Guardian - UK

Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre

Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe."

Benzinga

Biogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular Atrophy

On Tuesday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Biogen Inc.’s (NASDAQ: BIIB) supplemental New Drug Application (sNDA) for the high-dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA).

Benzinga

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease gene therapy. Indeed, the stock reached a 5-year high, marking its best session ever. But if you think the move…

Benzinga

Medicine price rises ‘necessary’ to secure investments, science minister says

Major firms have already shelved or paused planned UK pharmaceutical industry investments this year.

The Independent UK

Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility

‘We’re here to invest,’ says Darius Hughes as he calls comments by other pharma companies ‘a little harsh’

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO

Eli Lilly and Co. (NYSE:LLY) CEO Dave Ricks strongly criticized the United Kingdom's approach to drug pricing, describing it as "probably the worst country in Europe" for pharmaceutical prices.

Benzinga

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program.

The Guardian - UK

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

The Guardian - UK

Eli Lilly calls UK ‘worst country in Europe’ for drug prices; gold nears record high - as it happened

Spot gold trading just below Monday’s fresh record high

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Roche Targets Top Spot In Weight Loss Drug Market

Roche Holdings AG (OTC:RHHBY) on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO).

Benzinga

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market

Pfizer Inc. (NYSE:PFE) stock climbed 1.54% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ:MTSR), a developer of anti-obesity drugs.

Benzinga

Why MBX Biosciences Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket

Shares of MBX Biosciences, Inc. (NASDAQ:MBX) rose sharply in pre-market trading after the company announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism on Sep. 22.

International Business Times

Novartis Chief Eyes Ways To End Higher US Drug Prices: Media

Amid a threat of towering US tariffs, Swiss pharmaceutical giant Novartis is seeking ways to enable Americans to pay less for their medicines, its chief said in an interview published Saturday.

Benzinga

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds

Oscar Health Inc (NYSE:OSCR) just became one of Wall Street's buzziest policy trades. With ACA (Affordable Care Act) subsidy chatter swirling ahead of a possible government shutdown, the tech-driven insurer is drawing Hims Hers Health Inc (NYSE:HIMS) style moonshot comparisons — and short sellers may be sitting on a powder…

The Guardian - UK

NHS drug pricing is all about the art of the deal

Letter: Better negotiation with big pharma could ease the process, writes Andrew Dillon, in response to an article by Polly Toynbee about Donald Trump’s complaints about NHS pricing

The Guardian - UK

Novo Nordisk shares climb after positive anti-obesity pill results

Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.